Ares Management (NYSE:ARES) will report on Q3 2021.
Myovant Sciences Earnings Perspective: Return On Capital Employed
According to Benzinga Pro data, during Q2, Myovant Sciences (NYSE:MYOV) posted sales of $77.90 million. Earnings were up 67.99%, but Myovant Sciences still reported an overall loss of $18.35 million.